A XRCC4 mutant mouse, a model for human X4 syndrome, reveals interplays with Xlf, PAXX, and ATM in lymphoid development

Abstract

We developed a Xrcc4M61R separation of function mouse line to overcome the embryonic lethality of Xrcc4 deficient mice. XRCC4M61R protein does not interact with Xlf, thus obliterating XRCC4-Xlf filament formation while preserving the ability to stabilize DNA Ligase IV. X4M61R mice, which are DNA repair deficient, phenocopy the Nhej1-/- (known as Xlf -/-) setting with a minor impact on the development of the adaptive immune system. The core NHEJ DNA repair factor XRCC4 is therefore not mandatory for V(D)J recombination aside from its role in stabilizing DNA ligase IV. In contrast, Xrcc4M61R mice crossed on Paxx-/-, Nhej1-/-, or Atm-/- backgrounds are severely immunocompromised, owing to aborted V(D)J recombination as in Xlf-Paxx and Xlf-Atm double KO settings. Furthermore, massive apoptosis of post-mitotic neurons causes embryonic lethality of Xrcc4M61R -Nhej1-/- double mutants. These in vivo results reveal new functional interplays between XRCC4 and PAXX, ATM and Xlf in mouse development and provide new insights in the understanding of the clinical manifestations of human XRCC4 deficient condition, in particular its absence of immune deficiency.

Data availability

The xl file with raw data used in PCA analysis (Fig. 2G) has been depositied on DRYADhttps://doi.org/10.5061/dryad.547d7wm7x

The following data sets were generated

Article and author information

Author details

  1. Benoit Roch

    DGSI Laboratory, Institut Imagine, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Vincent Abramowski

    DGSI Laboratory, Institut Imagine, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Olivier Etienne

    Laboratoire de RadioPathologie, CEA, Fontenay-aux Roses, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Stefania Musilli

    DGSI Laboratory, Institut Imagine, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Pierre David

    Transgenesis lab, Institut Imagine, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Jean-Baptiste Charbonnier

    Institute for Integrative Biology of the Cell (I2BC), CEA, Gif-s-Yvette, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Isabelle Callebaut

    Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, CNRS, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. François D Boussin

    Laboratoire de RadioPathologie, CEA, Fontenay-aux Roses, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Jean-Pierre de Villartay

    DGSI Laboratory, Institut Imagine, INSERM, Paris, France
    For correspondence
    jean-pierre.de-villartay@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5987-0463

Funding

Institut National de la Santé et de la Recherche Médicale

  • Benoit Roch
  • Vincent Abramowski
  • Stefania Musilli
  • Jean-Pierre de Villartay

Agence Nationale de la Recherche (ANR-10-IAHU-01)

  • Benoit Roch
  • Vincent Abramowski
  • Stefania Musilli
  • Pierre David
  • Jean-Pierre de Villartay

Institut National Du Cancer (PLBIO 16-280)

  • Benoit Roch
  • Vincent Abramowski
  • Stefania Musilli
  • Jean-Baptiste Charbonnier
  • Isabelle Callebaut
  • Jean-Pierre de Villartay

Ligue Contre le Cancer (Equipe Labellisée)

  • Benoit Roch
  • Vincent Abramowski
  • Stefania Musilli
  • Jean-Pierre de Villartay

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were performed in compliance with the French Ministry of Agriculture's regulations for animal experiments (act 87847, 19 October 1987; modified in May 2001) after audit with "Comité d'Ethique en Expérimentation Animale (CEEA) Paris Descartes" (Apafis #25432-2019041516286014 v6)

Copyright

© 2021, Roch et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 696
    views
  • 133
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Benoit Roch
  2. Vincent Abramowski
  3. Olivier Etienne
  4. Stefania Musilli
  5. Pierre David
  6. Jean-Baptiste Charbonnier
  7. Isabelle Callebaut
  8. François D Boussin
  9. Jean-Pierre de Villartay
(2021)
A XRCC4 mutant mouse, a model for human X4 syndrome, reveals interplays with Xlf, PAXX, and ATM in lymphoid development
eLife 10:e69353.
https://doi.org/10.7554/eLife.69353

Share this article

https://doi.org/10.7554/eLife.69353

Further reading

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Kira A Cozzolino, Lynn Sanford ... Dylan J Taatjes
    Research Article

    Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.

    1. Chromosomes and Gene Expression
    Carlos Moreno-Yruela, Beat Fierz
    Insight

    Specialized magnetic beads that bind target proteins to a cryogenic electron microscopy grid make it possible to study the structure of protein complexes from dilute samples.